Document is current
Any future updates will be listed below
-
Authors
Mengist, Belayneh https://orcid.org/0000-0002-0363-8777
Davoodian, Najmeh
Lotfaliany, Mojtaba
Pasco, Julie A. https://orcid.org/0000-0002-8968-4714
Agustini, Bruno https://orcid.org/0000-0001-8735-2401
Forbes, Malcolm
Marx, Wolfgang https://orcid.org/0000-0002-8556-8230
Yu, Chenglong https://orcid.org/0000-0002-0546-2779
Neumann, Johannes T.
Lacaze, Paul https://orcid.org/0000-0002-0902-6798
Owen, Alice J.
McNeil, John J. https://orcid.org/0000-0002-1049-5129
Woods, Robyn L.
Berk, Michael https://orcid.org/0000-0002-5554-6946
Mohebbi, Mohammadreza https://orcid.org/0000-0001-9713-7211
- License Information
-
More Information
Article History
Received: 5 May 2026
Revised: 30 June 2026
Accepted: 10 July 2026
First Online: 17 July 2026
Ethics
Competing interests: The authors declare that they have no competing interests. JTN reports honoraria from Abbott, PHC, Roche Diagnostics, Siemens Healthineers, and SpinChip outside the submitted work. JTN is listed as co-inventor of an international patent on the use of a computing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1) as well as co-founder and shareholder of the ART-EMIS Hamburg GmbH.
Ethics approval: The ASPREE trial was conducted in accordance with the 2008 Declaration of Helsinki and approved by the ethics review board at each participating institution. Monash University Human Research Ethics Committee and the Alfred Hospital Human Research Ethics Committee approved the ALSOP sub-study and ASPREE-XT (Monash 4HREC CF11/1935/2011001094 and Alfred HREC 593/17). Trial registration: International Standard Randomised Controlled Trial Number Register (ISRCTN83772183) and ClinicalTrials.gov (NCT01038583). The Monash University Human Research Ethics Committee approved the current secondary analysis.
